Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial

von Minckwitz, G; Kümmel, Sherko; Vogel, P.; Hanusch, Claus; Eidtmann, Holger; Hilfrich, J.; Gerber, B.; Huober, J.; D. Costa, S.; Jackisch, Christian; Loibl, Sibylle; Mehta, K.; Kaufmann, M.; behalf of the German Breast Group, On

doi:10.1093/jnci/djn085

Public

Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial

Published in JNCI Journal of the National Cancer Institute • Apr 8, 2008

Authors:

G von Minckwitz

Sherko Kümmel

P. Vogel

Abstract

BACKGROUND: Among breast cancer patients, nonresponse to initial neoadjuvant chemotherapy is associated with unfavorable outcome. We compared the response of nonresponding patients who continued the same treatment with that of patients who switched to a well-tolerated non-cross-resistant regimen. ME...

Subject

Vinorelbine

Capecitabine

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!